APEXXNAR is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.1
APEXXNAR helps prevent invasive disease and pneumonia caused by 20 pneumococcal serotypes in individuals 18 years of age and older1
† Data extracted from routine national IPD surveillance data from England and Wales from 2000 to 2017.4 For adults aged 65+ years the number of IPD cases occurring in 2016/17 are described for 27 individual serotypes, including all those in PCV13 and PCV20.3,4
PCV13: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
PCV20: pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)
A short guide to conjugate vaccine technology
The safety profile and immunogenicity of APEXXNAR was evaluated in 4,552 adults in 6 trials1
Key information about dosing, administration and storage of APEXXNAR1
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021